Fox Run Management, L.L.C. Allogene Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

  • $433 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 07, 2022
BUY
$10.32 - $17.28 $157,018 - $262,915
15,215 New
15,215 $164,000
Q2 2022

Aug 12, 2022
SELL
$6.78 - $12.28 $113,307 - $205,223
-16,712 Closed
0 $0
Q1 2022

May 10, 2022
BUY
$7.65 - $15.29 $127,846 - $255,526
16,712 New
16,712 $152,000

Others Institutions Holding ALLO

# of Institutions
163
Shares Held
134M
Call Options Held
59.4K
Put Options Held
113K
View Full List

About Allogene Therapeutics, Inc.

ALLO Quotes by TradingView
  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $262M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email